Featured Research

from universities, journals, and other organizations

The Common Cold As Cancer Fighter? Saint Louis University Prof's Lifetime Work Moving Into Clinical Trials

Date:
December 17, 2003
Source:
Saint Louis University
Summary:
Can the common cold ever be a good thing? It is if you've figured out a way to genetically engineer the virus so that it fights and kills cancerous cells - while leaving healthy cells intact.

ST. LOUIS - Can the common cold ever be a good thing? It is if you've figured out a way to genetically engineer the virus so that it fights and kills cancerous cells - while leaving healthy cells intact.

Related Articles


That's been the work of Dr. William Wold and his colleagues at Saint Louis University School of Medicine for the last 30 years.

"The potential is understandably huge," said Wold, whose work has just received a U.S. patent after years of study.

Dr. Wold, chair of the department of molecular microbiology and immunology, and his colleagues Karoly Toth, Konstantin Doronin, Ann E. Tollefson, and Mohan Kuppuswamy have found a way to convert the relatively benign "adenovirus" that causes the common cold into an anti-cancer drug that attacks and destroys cancerous cells.

"Human cancer is currently treated with surgery, radiation therapy, or chemotherapy, depending on the cancer type," Wold said. "These treatments can be highly successful, but new therapies are required, especially for tumors that have become resistant to chemo- or radiation-therapy."

Wold's group has developed several new "adenovirus cancer gene therapy vectors," changing these genes so the virus will attack cancer cells.

"Some of our vectors are designed to destroy many different types of cancers, others are designed to be specific to colon or lung cancer. In preclinical testing these vectors were highly effective against cancerous tumors and did not harm normal tissues."

Wold and his colleagues have done this by modifying one gene so that the virus can grow in cancer cells but NOT normal cells and by boosting the activity of another gene that the virus normally uses to disrupt the cells it has infected. "When the virus infects cells, it takes the altered genes with it, and those genes attack cancer cells while leaving normal cells intact," Wold explained.

A U.S. patent (No. 6,627,190) was awarded this fall to Dr. Wold and his team of researchers. Pre-clinical testing is complete and is expected to move soon into clinical trials.

Now this patented technology has been issued and exclusively licensed to a company, Introgen Therapeutics, which made the announcement this morning. Introgen and VirRx, a biotechnology company founded by Wold and with a primary interest in cancer gene therapy, are collaborating on new therapies for cancer and other diseases.

"Our collaboration with Introgen has resulted in the pre-clinical development of an active anti-cancer product that we are eager to introduce into the clinic to further develop the technology," Wold said. "This patent demonstrates our innovation and the novelty of our approach.

"There is a long tradition of adenovirus research at Saint Louis University School of Medicine dating back to the 1950s, and it can be argued that SLU is the birthplace of adenovirus molecular virology," Wold said.

###

Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first M.D. degree west of the Mississippi River. Saint Louis University School of Medicine is a pioneer in geriatric medicine, organ transplantation, chronic disease prevention, cardiovascular disease, neurosciences and vaccine research, among others. The School of Medicine trains physicians and biomedical scientists, conducts medical research, and provides health services on a local, national and international level.


Story Source:

The above story is based on materials provided by Saint Louis University. Note: Materials may be edited for content and length.


Cite This Page:

Saint Louis University. "The Common Cold As Cancer Fighter? Saint Louis University Prof's Lifetime Work Moving Into Clinical Trials." ScienceDaily. ScienceDaily, 17 December 2003. <www.sciencedaily.com/releases/2003/12/031217072123.htm>.
Saint Louis University. (2003, December 17). The Common Cold As Cancer Fighter? Saint Louis University Prof's Lifetime Work Moving Into Clinical Trials. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2003/12/031217072123.htm
Saint Louis University. "The Common Cold As Cancer Fighter? Saint Louis University Prof's Lifetime Work Moving Into Clinical Trials." ScienceDaily. www.sciencedaily.com/releases/2003/12/031217072123.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins